Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
May 14, 2007
- JSMI Announces 70 Candidates for Switch OTC Drugs
May 14, 2007
- Banyu Committed to Simultaneous Global Development
May 14, 2007
- Nihon Medi-Physics Completes Nationwide Distribution System for FDG
May 14, 2007
- GENERIC NEWS IN BRIEF
May 14, 2007
- Given Imaging to Launch Capsule Endoscope
May 14, 2007
- Kyowa Hakko Submits NDA for KW-6002 Combination Therapy for Parkinson's Disease in US
May 14, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 14, 2007
- Sales of Nicotinell Show 2.5-Fold Increase: Novartis
May 14, 2007
- Crestor, Drug of Choice for High-Risk Patients: Prof. Teramoto
May 14, 2007
- Amgen K.K. to Create Independent Development, Marketing Systems
May 14, 2007
- Tokyo Municipal Hospitals Share Criteria for Selection of Generics
May 14, 2007
- 6 Tokyo Prefectural Hospitals to Reduce Number of Drugs Used
May 14, 2007
- Towa Creates New Division to More Promptly Supply Information Required by Users
May 14, 2007
- BUSINESS NEWS IN BRIEF
May 14, 2007
- DSP Aims at Annual Sales of \170 Mil. Per MR in FY2009
May 14, 2007
- Cancer Pain Killer Metastron Recommended for Approval
May 14, 2007
- Eplerenone, Topiramate, Rocuronium Recommended for Approval
May 14, 2007
- Substitute Products to Be Approved by Minor Change Notices
May 14, 2007
- REGULATORY NEWS IN BRIEF
May 14, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…